It may be one thing to see the words “cancer center” and “cancer drug” as generic generic words, but the American Cancer Society is going to change that.
The new drug and device, called AstroBiloxix, is the first drug to target both the metastatic and nonmetastatic forms of the disease.
This is important, because in many cases, metastatic cancer is only diagnosed when the patient has more than one type of cancer.
If the drug works, it will not only treat the first stage of metastatic cancers, but also help patients stay alive longer by helping them to maintain the healthy balance of their immune system, said Dr. Joseph J. Capra, director of the Center for Research on Cancer Immunotherapy and one of the authors of the paper published online in the journal PLOS ONE.
What makes this a big deal is that the disease is only detected in patients with multiple types of cancer, said Capra.
With more than a million people living with metastatic or nonmetastic forms of cancer worldwide, the need for a new drug has never been more urgent.
For many years, researchers have tried to find a new way to fight the disease by focusing on drugs that target one type or another of the cancer cells.
But there are so many competing cancer drugs available that many patients will not respond to any one of them, said Jennifer Hirsch, senior author of the study and director of breast cancer research at the Center.
“If you are looking for a way to combat metastatic tumor, you need to look for a cancer that targets two or more types,” she said.
In a way, the first part of this is kind of a double whammy for patients who have metastatic melanoma, said Hirsch.
Because melanoma can spread through blood, skin and other body tissues, some patients might be left with no choice but to take a drug to combat the disease, she said, adding that a drug called AZT, which is approved for melanoma in the U.S., has been shown to be effective against this cancer.
But it is not yet known whether this drug will be able to help patients with other types of cancers, such as prostate, colon and lung cancers.
Other drugs are also available that target only the cells that cause the disease in some cases, but they do not work as well in some cancers.
For example, there is no drug approved for treating breast cancer that can target the cells causing the disease but has been found to be a good choice for other cancers, said J. Craig Kellogg, a senior scientist at the National Cancer Institute in Bethesda, Maryland.
However, it is important to keep in mind that the new drug works best against cells that have already started to grow and spread, said Scott A. Giesbrecht, a research scientist at Northwestern University and one the authors on the study.
We’re trying to find the best way to get this drug into the market,” he said.
The next step is to find if the drug will work for patients with metastases to other types, and then work out if the new treatment will be effective.
It’s important that patients get the drug in the right dosage and be given it for a specific amount of time, Capra said.
For now, the trial is testing the drug against cancer cells in the liver, and the researchers expect to be able, at some point, to use it in the pancreas and other organs.
Although the drug is approved in the United States, the drugs are not yet available for use in the rest of the world.
Even if the FDA approves the drug, it could take a decade for it to be available in the marketplace, and some experts fear that even if the approval is successful, it might not be long before the drug becomes less effective in the body.
A trial for the drug has been planned for six months, CapRA said, and he expects to have more results and more patients participating in the trial by the end of the year.
Dr. J. Scott Giesbrodt, director, clinical and translational sciences, American Cancer Association.
More from TIME: